ABSTRACT
Background Tuberculosis (TB) remains a significant cause of mortality worldwide. Metagenomic next-generation sequencing has the potential to reveal biomarkers of active disease, identify coinfection, and improve detection for sputum-scarce or culture-negative cases.
Methods We conducted a large-scale comparative study of 427 plasma, urine, and oral swab samples from 334 individuals from TB endemic and non-endemic regions to evaluate the utility of a shotgun metagenomic DNA sequencing assay for tuberculosis diagnosis.
Findings We found that the choice of a negative, non-TB control cohort had a strong impact on the measured performance of the diagnostic test: the use of a control patient cohort from a nonendemic region led to a test with nearly 100% specificity and sensitivity, whereas controls from TB endemic regions exhibited a high background of nontuberculous mycobacterial DNA, limiting the diagnostic performance of the test. Using mathematical modeling and quantitative comparisons to matched qPCR data, we found that the burden of Mycobacterium tuberculosis DNA constitutes a very small fraction (0.04 or less) of the total abundance of DNA originating from mycobacteria in samples from TB endemic regions.
Interpretation Our findings suggest that the utility of a metagenomic sequencing assay for tuberculosis diagnostics is limited by the low burden of M. tuberculosis in extrapulmonary sites and an overwhelming biological background of nontuberculous mycobacterial DNA.
Funding This work was supported by the National Institutes of Health, the Rainin Foundation, the National Science Foundation, and the Bill and Melinda Gates Foundation.
Competing Interest Statement
I.D.V. has received research grants from the Bill and Melinda Gates Foundation, the National Institutes of Health, and the Rainin Foundation. P.B. has received research grants from the National Science Foundation. I.D.V. and P.B. are inventors on the patent US-2020-0048713-A1 titled "Methods of Detecting Cell-Free DNA in Biological Samples". The rights to the patent were licensed by Eurofins through Cornell University. I.D.V. is a Member of the Advisory Board and has stock in Karius Inc.
Funding Statement
This work was supported by the National Institutes of Health, the Rainin Foundation, the National Science Foundation, and the Bill and Melinda Gates Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of the Johns Hopkins Bloomberg School of Public Health gave ethical approval for this work (protocol 00002185). Institutional Review Board of Cornell University gave ethical approval for this work (protocols 1612006853, 1612006851). Clinical Trials Review Committee of the Foundation for Innovative New Diagnostics gave ethical approval for this work (protocol 1612006851). Research and Ethics Committee of Makerere University School of Medicine gave ethical approval for this study (protocol 2017-020). Institutional Review Board of Weill Cornell Medicine gave ethical approval for this study (protocols 9402002786, 1207012730, 0710009490). Institutional Review Board of Stanford University gave ethical approval for this work (protocol 17666). Research Ethics Board of the University of Philippines Manila gave ethical approval for this work (protocol UPMREB 2018-252-01).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The sequence data for the non-endemic urine cohort was deposited in the database of Genotypes and Phenotypes (dbGaP, accession number phs001564v3.p1). The sequence data for the non-endemic plasma cohort was deposited in the Sequence Read Archive (accession number PRJNA263522). The sequence data generated in the scope of this study will be deposited in the Sequence Read Archive.
